Multiple sclerosis, or MS, is a progressive chronic disorder of the
nervous system that is most often seen in patients between the ages of
20 and 40. In MS, the immune system attacks a protein called myelin,
which forms a protective sheet around neurofibers. When myelin is
damaged by MS, neurons struggle to communicate, leading to an
accumulation of neuronal loss, atrophy and significant disability over
time. We are committed to meeting the needs of patients with MS, and
we are currently supporting treatment options that promote nerve
protection and facilitate neuronal regeneration.
Parkinson’s disease is the second most-common neurodegenerative
disorder, affecting more than 10 million people worldwide. In addition
to our therapy for advanced Parkinson’s, we are currently exploring
other pathways that could provide patients with a new method of
treatment for this progressive chronic disease. We are also developing
a new delivery system to enhance the patient and caregiver experience
while administering our existing therapy for Parkinson’s disease.